Home » Newsletters » BioWorld Science

BioWorld Science

April 17, 1998

View Archived Issues

New growth factor inhibitors with antiproliferative and antipermeability effects

ViroPharma's new antiinfluenza agents

Selective MMP-13 inhibitors in the pipeline at Monsanto

NeoPharm: Q4 and year-end 1997 highlights

Roche: Q1 1998 highlights

Medco: Q1 1998 highlights

Novel dopaminergic compounds in the pipeline at ADIR

Another market introduction for irbesartan

Immunex reacquires worldwide rights to soluble receptor compounds from HMR

OraVax licenses CagA H. pylori antigen to Biomerica

Theratechnologies receives additional funding for photodynamic therapy research

Varian and GenVec collaborate on novel cancer treatments

Ampligen to be evaluated in U.S. phase III trials for chronic fatigue syndrome

OGS and Pfizer to collaborate on Alzheimer's disease research

Allelix gets go-ahead to start U.K. trials for antimigraine drug

FDA clears new indication for Prevacid

FDA issues approvable letter for expanded use of Ceprate SC System

AnorMED seeks licensing partner for phase II rheumatoid arthritis drug

Selective beta3-adrenoceptor agonists from Merck & Co. for obesity, diabetes

Agents for urinary incontinence and IBS in development at Pharmacia & Upjohn

ICAgen and Lilly disclose potassium channel inhibitors

Novel polymer chemotherapeutic presented at ACS meeting

FDA requests additional information for CP-Cardiosol IND

More GH secretagogues in the pipeline at Merck & Co.

Another CS-A4 derivative discovered by Ajinomoto

Boston Life Sciences' product pipeline is maturing, company executive says

Inhale licenses technology from Initiatech

SuperGen's Nipent granted orphan drug status

Phase I data reported on CoCensys' ganaxolone tablet formulation

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...